---
document_datetime: 2023-09-21 17:28:48
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/xigris-epar-procedural-steps-taken-authorisation_en.pdf
document_name: xigris-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3868885
conversion_datetime: 2025-12-21 11:19:07.440117
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company Eli Lilly Nederland B.V. submitted on 15 January 2001  an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Xigris, in  accordance  with  the  centralised  procedure  falling  within  the  scope  of  Part  A  of  the  Annex  to Council Regulation No (EEC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur:

Pharm. G. De Greef

Co-Rapporteur:

Dr. M. Haase

Medicinal product no longer authorised Licensing status: Xigris has been given a Marketing Authorisation in US on 21 November 2001: The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 30 January 2001 · The Rapporteur's first assessment report was circulated to all CPMP Members on 19 April 2001 and  23  April  2001.  The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP Members on 28 April 2001 · During the meeting on 29-31 May 2001 the CPMP agreed on the consolidated list of questions to be sent to the company. The final consolidated list of questions was sent to the company on 31 May 2001. · The company submitted the responses to the consolidated list of questions on 13 July 2001 · The Rapporteur circulated the response assessment report on the company's responses to the list of questions to all CPMP Members on 27 and 28 August 2001. · During the meeting on May 2002 the CPMP, in the light of the overall data submitted and the scientific  discussion  within  the  Committee,  issued  a  positive  opinion  under  exceptional circumstances  for  granting  a  Marketing  Authorisation  to  Xigris  for  the  treatment  of  adult patients  with  severe  sepsis  with  multiple  organ  failure  when  added  to  best  standard  care  (for further information see Section 5.1 of SPC) on 30 May 2002. The CPMP Opinion was adopted with additional Specific obligations and Follow up measures that the company agreed to fulfil on an ongoing basis post-opinion. · The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 22 August 2002.